

This is a promotional email intended for healthcare professionals only.



LEADING
THE WAY

WHO EXPANDS RECOMMENDATION FOR VEKLURY TO PATIENTS WITH SEVERE COVID-19¹

Dear [Doctor],

I'm writing with important news for the treatment of patients with COVID-19.

The WHO now conditionally recommends VEKLURY for patients with severe COVID-19.¹

VEKLURY is the only antiviral treatment recommended by the WHO for patients with:¹

Non-severe COVID-19

- Absence of any criteria for severe or critical COVID-19

Severe COVID-19

- Oxygen saturation <90% on room air
- Signs of pneumonia
- Signs of severe respiratory distress

The panel did not find evidence of benefit in patients with critical COVID-19 and recommends against the use of VEKLURY in critical patients.*¹

Data supporting the new recommendation

The WHO conditional recommendation for VEKLURY's use in the treatment of patients with severe COVID-19 is mainly driven by the final results of the WHO-sponsored SOLIDARITY study.²

The WHO SOLIDARITY primary outcome assessed in-hospital mortality, both overall and subdivided by disease severity at entry.²

For patients who required supplemental oxygen at baseline, SOLIDARITY showed:²

17%

lower relative risk of death or progression to IMV vs SoC (RR: 0.83; 95% CI: 0.75–0.93)

13%

lower relative risk of mortality vs SoC (RR: 0.87; 95% CI: 0.76–0.99)

VEKLURY had no significant effect on patients with COVID-19 who were already being ventilated²

These findings complement results from NIAID ACTT-1, a double-blind placebo-controlled trial in which a post-hoc subgroup analysis showed a mortality reduction for VEKLURY vs placebo in patients on low-flow oxygen at baseline (HR: 0.30; 95% CI: 0.14–0.64). VEKLURY did not demonstrate a mortality benefit in the overall population or other baseline oxygen subgroups in either ACTT-1 or SOLIDARITY.^{1,3}

[View the new WHO guideline here](#)



In addition to the WHO, VEKLURY is recommended by several major guidelines worldwide, including the NIH, NICE, ESCMID, IDSA, MHLW, AWMF and COVRIIN, supporting VEKLURY's role as the COVID-19 antiviral standard of care in hospitals.^{1,4–10}

This data reflects the robust body of evidence for VEKLURY, highlighting its ability to reduce disease progression, fast forward to recovery and reduce mortality for COVID-19 patients.^{1,3}

To help your patients benefit, initiate VEKLURY right away in appropriate patients upon hospitalisation.¹¹

If you would like any additional information, I can follow up with you directly.

Best wishes,

[Insert contact details here]

VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID19) in adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment), and adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

Please click [here](#) to access the Prescribing Information.

ACTT, Adaptive COVID-19 Treatment Trial; ARDS, acute respiratory distress syndrome; AWMF, Association of Scientific Medical Societies in Germany; CI, confidence interval; COVID-19, coronavirus disease 2019; COVRIIN, Department of Intensive Care Medicine, Infectiology and Emergency Medicine; HR, hazard ratio; IDSA, Infectious Diseases Society of America; MHLW, Ministry of Health, Labour and Welfare; NIAID, National Institute of Allergy and Infectious Diseases; NICE, National Institute of Health and Care Excellence; NIH, National Institutes of Health; RR, relative risk; SoC, standard of care; WHO, World Health Organisation.

* Critical disease is defined as requiring life-sustaining treatment, ARDS, sepsis or septic shock.¹

References:

1. Agarwal A, et al. BMJ. 2020; 370: m3379.
2. WHO Solidarity Trial Consortium. Lancet. 2022. DOI: 10.1016/S0140-6736(22)00519-0.
3. Beigel JH, et al. N Engl J Med. 2020; 383: 1813–1826.
4. NIH. Therapeutic management of adults with COVID-19. Available at: <https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalizedadults--therapeutic-management/>. Accessed September 2022.
5. NICE. Guideline [NG191]. COVID-19 rapid guideline: managing COVID-19. Available at: <https://app.magicapp.org/#/guideline/L4Qb5n/section/ERYAXn>. Accessed September 2022.
6. Bartoletti M, et al. Clinical Microbiology and Infection. DOI: 10.1016/j.cmi.2021.11.007.
7. IDSA. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available at: <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatmentand-management/>. Accessed September 2022.
8. Eleven things you need to know NOW about COVID-19. Available at <https://www.mhlw.go.jp/content/jun2022.pdf>. Accessed September 2022.
9. Kluge et al. 3-Leitlinie - Empfehlungen zur stationären Therapie von Patienten mit COVID-19. Available at https://www.awmf.org/uploads/tx_szleitlinien/113-001LGI_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-03.pdf. Accessed September 2022.
10. Infographic: COVID-19: Drug and non-drug therapy recommendations by disease phase. Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/COVRIIN_Dok/Infografik-Therapieempfehlungen.pdf?__blob=publicationFile. Accessed September 2022.
11. [Insert reference to local VEKLURY Product Information.](#)

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to Gilead at safety_FC@gilead.com or +44 (0) 1223 897500.

This information is intended for healthcare professionals.

September 2022 GLB-VKY-0046

This email was received because you have opted in to receiving promotional emails from Gilead. [Privacy Policy](#) | [Unsubscribe](#)